<DOC>
	<DOC>NCT03046056</DOC>
	<brief_summary>The primary objective of this study is to evaluate the efficacy of filgotinib, when compared to placebo, in establishing clinical remission in participants with Crohn's disease involving the small bowel. Participants will have the option to enter a separate long-term extension study if they meet eligibility requirements.</brief_summary>
	<brief_title>Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Key Males or nonpregnant, nonlactating females, ages 18 to 75 years, inclusive based on the date of screening visit Moderately or severely active CD Minimum duration of CD of at least 6 months Presence of diseased SB segments in at least 1 of the following segments: terminal ileum, distal ileum, or jejunum Patients with additional colonic involvement of CD are permitted in study as long as SBCD is present Previously demonstrated an inadequate clinical response, loss of response to, or intolerance to at least 1 of the following agents (depending on current country treatment recommendations/guidelines): Corticosteroids Immunomodulators Tumor necrosis factoralpha (TNFÎ±) antagonists Vedolizumab Willing and able to undergo magnetic resonance enterography (MRE) per protocol requirements Key Presence of symptomatic or clinically significant (eg, obstructive or symptomatic) strictures or stenosis. Presence of fistulae Evidence of short bowel syndrome Presence of ulcerative colitis, indeterminate colitis, ischemic colitis, fulminant colitis, or toxic megacolon History of total colectomy, hemicolectomy, presence of ileostomy or colostomy, or likely requirement for surgery during the study Use of any prohibited concomitant medications as described in the study protocol Active tuberculosis (TB) or history of latent TB that has not been treated Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>